Tyrosine and its catabolites: from disease to cancer

• Autorzy: Tanguay R. M. , Jorquera R. , Poudrier J. , St-Louis M.
• Języki publikacji: EN

Abstrakty

EN

Hereditary tyrosinemia type I (HT I, McKusick 276700) is a metabolic disease with a pattern of autosomal recessive inheritance. The disease is caused by a deficiency of the enzyme involved in the last step in the degradation of the amino acid tyrosine, fumarylacetoacetate hydrolase (FAH). The result of this block is the accumulation of catabolites some of which have been proposed to be highly toxic due to their alkylating potential. In humans, hereditary tyrosinemia is often associated with the development of hepatocellular carcinoma in young patients. The reasons for the high incidence of hepatocellular carcinoma are unknown but it has been suggested that it may be caused by accumulated metabolites such as fumarylacetoacetate (FAA) and maieylace­toacetate (MAA). The various mutational defects in the FAH gene are reviewed. The use of two mouse models of this disease to study the molecular basis of the pathologies associated with HT I are discussed. Finally, some preliminary data on the mutagenic potential of FAA and MAA in a gene reversal assay are presented.

Słowa kluczowe

EN

metabolic disease; catabolite; fumarylacetoacetate hydrolase; tyrosinemia type I; hepatocellular carcinoma; mutagenesis; tyrosine; cancer; hepatocarcinogenesis; maleylacetoacetate

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 1996
• Tom: 43
• Numer: 1
• Opis fizyczny: p.209-216,fig

Twórcy

autor

Tanguay R. M.

• Universite Laval, Ste-Foy, Quebec, Canada G1K 7P4

autor

Jorquera R.

autor

Poudrier J.

autor

St-Louis M.

Bibliografia

• 1. Kvittingen, E.A. (1986) I lereditary tyrosinemia type 1 — an overview. Scand. J. Clin. Ljib. Invest. 46,27-34.
• 2. Mitchell, G.A., Lambert. M. & Tanguay, R.M. (1995) Hypertyrosincmia; in The Metabolic and Molecular Bases of Inherited Disease (Scriver, C.R., Beaudet, A.L., Sly, W.S. & Valle, D., eds.) pp. 1077-1106, McGraw-Hill, New York.
• 3. Lindblad, B., Lindstedt.S. &Steen,G.(1977)On the enzymic defects in hereditary tyrosincmia. Proc. Natl. Acad. Sci. U.S.A. 74.4641-4645.
• 4. Gagne, R., Lescault, A., Grenier, A., Laberge, C., Melan?on,S.B. & Dallaire. L.0982) Prenatal dia­gnosis of hereditary tyrosinaemia: Measu­rement of succinvlacetone in amniotic fluid. Prenat. Diagn. 2.185-188.
• 5. Mitchell, G., Larochelle, J., Lambert, M., Michaud, J.,Grenier, A., Ogier, H., Gaulhier, M„ I-acroix,J., Vanasse,M., Larbrisseau, A., Paradis, K., Weber, A., Lefevre, Y.. Melanvon, S. & Dallaire, L. (1990) Neurological crises in hereditary tvrosinemia. N. Engl. /. Med. 322, 432-437. '
• 6. DeBraekeleer, M. & Larochelle, J. (1990) Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean. Am. J. Hum. Genet. 47, 302-307.
• 7. Grompe, M., St-Louis, M., Demers, S.I., Al-Dhalimv, M., Leclerc, B. & Tanguay, R.M. (1994) A single mutation of the tumarvlace- toacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. N. Engl. ). Med. 331,353-357.
• 8. Poudrier, J., St-Louis, M„ l.etlre, F., Gibson. K., Pr«?vost,C., Larochelle, J. & Tanguay, R.M. (1996) Frequency of the 1VS12+5G -> A splice mutation of the fumarvlacetoacetate hydrolase gene in carriers of hereditary tyrosinaemia in the French Canadian population of Saguenay-Lac-St-Jean. Prenat. Diagn. 16, 59-64.
• 9. Tanguay, R.M., Laberge, C., Lescault, A., Valet, J.P., Duband, J.L. & Quenneville, Y. (1984) Molecular basis of hereditary tyrosinemias. Proof of the primary defect by western blot; in Advances in Gene Technology: Human Genetic Disorders (Ahmad, F., Black, S., Schultz, J., Scott, W.A. & Whclan, W.J., eds.) pp. 256-257,1CSU, Cambridge.
• 10. Tanguay, R.M., Valet, J.P., Lescault, A., Duband, J.L, I-aberge, C., Lettre, F. & Plante, M. (1990) Different molecular basis for fumarvlaceto­acetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). Am. J. Hum. Genet. 47,308-316.
• 11. Berger, R., van Faassen, H., Taaninan, J.W., Vries, H.D. & Agsteribbe, E. (1987) Type I tyrosinemia: Lick of immunologically detectable t'umaryl- acetoacetase enzyme protein in tissues and cell extracts. Pediatr. Res. 22,394-398.
• 12. Agsteribbe, E., van Faassen, H., Hartog, M.V., Reversma, T., Taanman, J.-W., Pannekoek, H., F.vers, R.F., Welling, G.M. & Berger, R. (1990) Nucleotide sequence of cDN A encoding human fumarylacetoacetase. Nucleic Acids Res. 18,1887.
• 13. Phaneuf, D., Labelle, Y., Bérubé, D., Arden, K., Cavenee, W., Gagné, R. & Tanguay, R.M. (1991) Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: Assignment of the gene to chromosome 15. Am. j. Hum. Genet. 48,525-535.
• 14. Phaneuf, D., l.ambert, M., Laframboise, R., Mitchell, G., Lettre, F. & Tanguay, R.M. (1992) Type 1 hereditary tyrosinemia: Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient. J. Clin. Invest. 90,1185-1192.
• 15. Labelle, Y., Phaneuf, D., Ixxilerc, B. & Tanguay, R.M. (1993) Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity. Hum. Mol. Genet. 2,941-946.
• 16. Labelle, Y., Puymirat, J. & Tanguay, R.M. (1993) Ixx-alization of cells in the rat brain expressing fumarylacetoacetate hydrolase, the deficient enzyme in hereditary tyrosinemia type 1. Hiochim. Biophys. Acta 1180,250-256.
• 17. St-I.ouis, M., Leclerc, B., Laine, J., Salo, M.K., Holmberg, C. & Tanguay, R.M. (1994) Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosincmia type I. Hum. Mol. Genet. 3,69-72.
• 18. Grompe, M. & Al-Dhalimy, M. (1993) Mutations of the fumarylacetoacetate hydrolase gene in four patients with hereditary tyrosinemia type I. Hum. Mutat. 2,85-93.
• 19. Lindstedt,S., Holme, E., Lock, H.A., Hjalmarson, O. & Strandvik, B. (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxvgenase. Lancet 340,813-817.
• 20. Laberge, C., Lescault, A. & Tanguay, R.M. (1986) Hereditary tyrosinemias (type I), A new vista on tyrosine toxicity and cancer; in Essential Nutri­ents in Carcinogenesis (Poirier, L.A., Newberne, P.M. & Pariza, M.W., eds.) pp. 209-221, Plenum Press, New York.
• 21. Kelsey, G., Ruppert, S., Beermann, F., Grund,C, Tanguay, R.M. & Schutz, G. (1993) Rescue of mice homozygous for lethal albino deletions. Implications for an animal model for the human liver disease tyrosinemia type 1. Genes & Dev. 7, 2285-2297.
• 22. Gluecksohn-Waelsch, S. (1979) Genetic control of morphogenetic and biochemical differen­tiation: Lethal albino deletions in the mouse. Cell 16,225-237.
• 23. Kelsey, G. & Schutz, G. (1993) Lessons from lethal albino mice. Curt. Opin. Genet. Dev. 3. 259-264.
• 24. Groinpe, M, Al-Dhalimv, M., Finegold, M., Ou, C.-N., Burlingame, T., Kennaway, N.G. & Soriano, P. (1993) Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes & Dev. 7, 2298^-2307.
• 25. Grompe, M., Lindstedt, S., Al-Dhalimy, M., Kennaway, N., Papaconstantinou, J., Torres-Ramos, C.A., Ou, C.-N., Burlingame, T., & Finegold, M. (1995) Pharmacological correc­tion of neonatal lethal hepatic-dysfunction in a murine model of hereditary tyrosinemia type I. Nat. Genetics 10.453-460.
• 26. Ellis, M.K., Whitfield, A.C., Cowans. L.A., Auton, T.R., Provan, W.M., Lock, E.A. & Smith, L.L. (1995) Inhibition of 4-hydroxvphenyl- pyruvate dioxygenase by 2-(2-nitro-4-triflu- oromethylbenzoyl)-cvclohexane-l,3-dione and 2-(2-chloro-4-methanesuIfonylbenzovl)-cyclo- hexane-l,3-dione. Toxicol. Appl. Pharmacol. 133, 12-19.
• 27. Fernandez-Canon, J.M. & Penalva, M.A. (1995) Fungal metabolic model for human type I hereditary tyrosinaemia. Proc. Natl. Acad. Sci. U.S.A. 92,9132-9136.
• 28. Kvittingen, E.A., Rootwelt, H., van-Dam, T., van Faassen, H. & Berger, R. (1992) Hereditary tyrosinemia type I: Lack of correlation between clinical findings and amount of imrnuno- reactive fumarylacetoacetase protein. Pediatr. Res. 31,43-46.
• 29. Kvittingen, E.A., Rootwelt, H., Brandtzaeg, P., Bergan, A. & Berger, R. (1993) Hereditary tyro­sinemia type I: Self-induced correction of the fumarvlacetoacetase defect. /. Clin. Invest. 91, 1816-1821.
• 30. Phaneuf, D., Hadchouel, M., Tanguav, R.M., Br&rhot, G & Ferry, N. (1995) Correction of fumarylacetoacetate hydrolase deficiency (type I tyrosinemia) in cultured human fibroblasts by retroviral-niediated gene transfer. Biochem. Biophys. Res. Commun. 208,957-963.
• 31. Grossman, M., Raper, S.E., Kozarsky, K., Stein, E.A., Engelhardt, J.F., Muller, D., Lupien, P.J. & Wilson, J.M. (1994) Succesful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat. Genctics 6, 335-341.
• 32. Hurford, R.K., Dranoff, G., Mulligan, R.C. & Tepper, R.l. (1995) Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat. Genetics 10,430-435. 33. Glatt, H. (1990) Endogenous mutagens derived from amino acids. Mutation Res. 238, 235-243.